Therapeutic antibodies are among the most widely used biologic medicines, yet detecting subtle structural differences in these complex proteins remains challenging. Researchers in Japan have established a nuclear magnetic resonance (NMR) strategy that reveals residue-specific structural features of antibodies without the need for isotope labeling.

The approach enables atomic-level evaluation of antibody structure, glycosylation, and molecular dynamics, providing a practical platform for quality assessment of biologic drugs and biosimilars.

Cisplatin (Cis) is an anticancer agent used to treat several types of cancers, including testicular cancer. However, despite its therapeutic efficacy, it increases the levels of reactive oxygen species (ROS), which damage healthy tissues and cells, resulting in tissue toxicity. This study aimed to examine the healing effect of selenium (Se) on Cis-induced testicular injury in male rats by evaluating testicular weight and monitoring the levels of oxidative stress and reproductive function markers in testicular homogenates.

This March, join the Alliance for Clinical Trials in Oncology (Alliance) and the Alliance Foundation Trials (AFT) in spotlighting colorectal cancer, the second leading cause of cancer-related death in the United States, behind only lung cancer, according to the National Cancer Institute. Last year, an estimated 155,000 Americans received a diagnosis of colon or rectal cancer, and about 53,000 died from the disease. Alliance has 10 active trials focused on improving treatments for colorectal cancers as well as others aimed at ways to prevent the disease or catch it very early when symptoms are most easily and effectively treated.

Neuroscientists at King’s College London have pinpointed a mechanism behind the increased neural connectivity seen in very early stages of Alzheimer’s disease.  Published in Translational Psychiatry, the study also demonstrated that a cancer medication has the potential to reduce this hyperconnectivity. 

A new report from the University of Oklahoma’s Native Nations Center for Tribal Policy Research examines barriers Native patients face when seeking cancer care, including challenges related to the Indian Health Service Purchased/Referred Care program. The report is designed to help tribal leaders better understand how the referral system works and where gaps in access to specialty cancer treatment may occur.

Peter WT Pisters, M.D., president of The University of Texas MD Anderson Cancer Center, was honored today with the Charles M. Balch, M.D., Distinguished Service Award at the Society of Surgical Oncology (SSO) 2026 Annual Meeting in recognition of his substantial contributions and leadership in the field of surgical oncology. 

A naturally occurring byproduct of liver metabolism–the ketone body, β-hydroxybutyrate (BHB)–can strengthen the fitness and antitumor activity of CAR T cells. The findings, reported on March 6, 2026 in the journal Cell, by Arc Institute and Stanford University scientists, together with colleagues from the University of Pennsylvania, highlight a potential new way to enhance cancer immunotherapies. The team, led by Maayan Levy, demonstrated that BHB—a metabolite produced after prolonged fasting or when on a ketogenic diet—can act as a powerful fuel source for T cells used in immunotherapy. BHB was found to reshape both T cell energy production and gene regulation in ways that improve tumor control across multiple cancer models.